Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Are These Five Stocks Plunging on Thursday?

Chesapeake Energy Corporation (NYSE:CHK) was off by as much as 4.5% in morning trade before rallying to being down 1.22% as shares remain volatile given the low natural gas prices. With the price of the commodity trading for just $2.27/mcf at Henry Hub, natural gas spot prices are not as strong as the bulls had hoped as warmer weather and higher-than-expected inventories weigh on sentiment. Although Chesapeake Energy Corporation (NYSE:CHK) shares are down 66% year-to-date, shares remain attractive for long term investors given the cheap valuation. Carl Icahn’s Icahn Capital LP owned 73.05 million shares of Chesapeake at the end of June.

Follow Chesapeake Energy Corp (NYSE:CHK)
Trade (NYSE:CHK) Now!

On a separate matter, ArcelorMittal SA (ADR) (NYSE:MT) is down by 5.6% as investors become less optimistic on the stock’s future. The world’s largest steel maker reported a disappointing $711 million loss for third quarter, as demand fell due to a weakening Chinese economy. ArcelorMittal SA (ADR) (NYSE:MT) management also cut guidance and suspended the dividend. Shares are down by more than 50% year-to-date. Bulls hope China’s economy can recover quickly so steel demand can come back.

Follow Arcelormittal S A Luxembourg (NYSE:MT)
Trade (NYSE:MT) Now!

Last but not least, shares of Derma Sciences Inc (NASDAQ:DSCI) has slid by 27% after the company announced it will terminate Phase 3 clinical trials that evaluate aclerastide for diabetic foot ulcers healing.

“This action is based on futility determinations conducted by the Data Monitoring Committee (DMC) for the planned, pre-specified interim analyses regarding the primary efficacy endpoint of confirmed complete wound closure of the target ulcer within 12 weeks of the start of treatment. The decision to end the studies followed the recommendation by the DMC to stop enrollment in the studies. … We are also halting all development work with DSC127 in scar reduction and radiation dermatitis. The development program termination eliminates a projected cash burn of approximately $5 million per quarter in 2016,” the company said in a statement.

Derma Sciences plans to focus its attention to grow its advanced wound care net sales and increase its margins. The company had $49.4 million of cash and $12 million of long-term investments as of September 30. Our data shows hedge funds are bullish on Derma Sciences Inc (NASDAQ:DSCI). A total of 17 funds owned $113.18 million of Derma Sciences shares at the end of the second quarter, accounting for 61.40% of the float.

Follow Derma Sciences Inc. (NASDAQ:DSCI)
Trade (NASDAQ:DSCI) Now!

Disclosure:None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...